Payment Breakdown by Category
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $13,131 | 870 | 100.0% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $1,476 | 115 | $0 (2022) |
| Genentech USA, Inc. | $1,132 | 53 | $0 (2022) |
| Merck Sharp & Dohme LLC | $1,072 | 80 | $0 (2023) |
| Amgen Inc. | $909.91 | 61 | $0 (2022) |
| Celgene Corporation | $894.76 | 35 | $0 (2023) |
| Novartis Pharmaceuticals Corporation | $801.49 | 68 | $0 (2022) |
| Janssen Biotech, Inc. | $747.62 | 76 | $0 (2023) |
| PFIZER INC. | $592.94 | 52 | $0 (2023) |
| Astellas Pharma US Inc | $539.98 | 28 | $0 (2023) |
| Incyte Corporation | $495.93 | 28 | $0 (2023) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $57.33 | 2 | Exelixis Inc. ($31.03) |
| 2023 | $516.17 | 27 | Janssen Biotech, Inc. ($74.55) |
| 2022 | $963.58 | 55 | E.R. Squibb & Sons, L.L.C. ($192.96) |
| 2021 | $1,287 | 74 | Celgene Corporation ($268.10) |
| 2020 | $505.75 | 32 | Astellas Pharma US Inc ($41.41) |
| 2019 | $2,876 | 212 | Merck Sharp & Dohme Corporation ($439.08) |
| 2018 | $3,278 | 225 | E.R. Squibb & Sons, L.L.C. ($488.99) |
| 2017 | $3,648 | 243 | Genentech USA, Inc. ($391.40) |
All Payment Transactions
870 individual payment records from CMS Open Payments — Page 1 of 35
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 08/30/2024 | ABBVIE INC. | EPKINLY (Drug), IMBRUVICA | Food and Beverage | In-kind items and services | $26.30 | General |
| Category: ONCOLOGY | ||||||
| 05/21/2024 | Exelixis Inc. | CABOMETYX (Drug) | Food and Beverage | In-kind items and services | $31.03 | General |
| Category: Renal Cell Carcinoma (RCC) Hepatocellular Carcinoma (HCC) Differentiated Thyroid Cancer (DTC) | ||||||
| 12/05/2023 | Pharmacyclics LLC, An AbbVie Company | IMBRUVICA (Drug), EPKINLY | Food and Beverage | In-kind items and services | $23.92 | General |
| Category: ONCOLOGY | ||||||
| 10/13/2023 | Takeda Pharmaceuticals U.S.A., Inc. | ICLUSIG (Drug) | Food and Beverage | In-kind items and services | $18.33 | General |
| Category: ONCOLOGY | ||||||
| 09/25/2023 | Janssen Biotech, Inc. | DARZALEX (Biological), TECVAYLI | Food and Beverage | In-kind items and services | $19.37 | General |
| Category: Oncology | ||||||
| 09/21/2023 | Takeda Pharmaceuticals U.S.A., Inc. | ICLUSIG (Drug) | Food and Beverage | In-kind items and services | $20.20 | General |
| Category: ONCOLOGY | ||||||
| 06/27/2023 | EMD Serono, Inc. | BAVENCIO (Drug) | Food and Beverage | Cash or cash equivalent | $16.42 | General |
| Category: Oncology | ||||||
| 06/21/2023 | Astellas Pharma US Inc | Xospata (Drug) | Food and Beverage | In-kind items and services | $28.64 | General |
| Category: Oncology | ||||||
| 06/14/2023 | Seagen Inc. | ADCETRIS (Biological) | Food and Beverage | In-kind items and services | $14.52 | General |
| Category: Oncology | ||||||
| 06/13/2023 | GENZYME CORPORATION | JEVTANA (Drug) | Food and Beverage | In-kind items and services | $16.83 | General |
| Category: Oncology | ||||||
| 06/05/2023 | MorphoSys, US Inc. | MONJUVI (Drug) | Food and Beverage | In-kind items and services | $14.99 | General |
| Category: Oncology | ||||||
| 05/23/2023 | G1 Therapeutics, Inc. | COSELA (Drug) | Food and Beverage | Cash or cash equivalent | $21.27 | General |
| Category: ONCOLOGY | ||||||
| 05/17/2023 | Celgene Corporation | REBLOZYL (Biological) | Food and Beverage | Cash or cash equivalent | $20.55 | General |
| Category: Hematology | ||||||
| 05/10/2023 | BeiGene USA, Inc. | BRUKINSA (Drug) | Food and Beverage | In-kind items and services | $14.96 | General |
| Category: Oncology | ||||||
| 04/28/2023 | Incyte Corporation | MONJUVI (Drug) | Food and Beverage | Cash or cash equivalent | $20.39 | General |
| Category: Oncology | ||||||
| 04/05/2023 | Kite Pharma, Inc. | — | Food and Beverage | In-kind items and services | $17.34 | General |
| 03/31/2023 | Janssen Biotech, Inc. | DARZALEX (Biological), TECVAYLI | Food and Beverage | In-kind items and services | $15.04 | General |
| Category: Oncology | ||||||
| 03/30/2023 | Puma Biotechnology, Inc. | — | Food and Beverage | In-kind items and services | $15.99 | General |
| 03/21/2023 | Merck Sharp & Dohme LLC | KEYTRUDA (Biological), WELIREG, LYNPARZA | Food and Beverage | In-kind items and services | $18.54 | General |
| Category: ONCOLOGY | ||||||
| 03/14/2023 | GENZYME CORPORATION | JEVTANA (Drug) | Food and Beverage | In-kind items and services | $20.06 | General |
| Category: Oncology | ||||||
| 03/07/2023 | EMD Serono, Inc. | BAVENCIO (Drug) | Food and Beverage | Cash or cash equivalent | $14.23 | General |
| Category: Oncology | ||||||
| 03/01/2023 | Janssen Biotech, Inc. | IMBRUVICA (Drug) | Food and Beverage | In-kind items and services | $24.95 | General |
| Category: Oncology | ||||||
| 02/23/2023 | PFIZER INC. | XTANDI (Drug), ORGOVYX, COMIRNATY | Food and Beverage | In-kind items and services | $16.09 | General |
| Category: ONCOLOGY | ||||||
| 02/14/2023 | Janssen Biotech, Inc. | DARZALEX (Biological), TECVAYLI | Food and Beverage | In-kind items and services | $15.19 | General |
| Category: Oncology | ||||||
| 02/10/2023 | Daiichi Sankyo Inc. | Enhertu (Drug) | Food and Beverage | In-kind items and services | $17.65 | General |
| Category: ONCOLOGY | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 5 | 91 | 217 | $56,427 | $14,820 |
| 2022 | 7 | 175 | 439 | $96,872 | $29,326 |
| 2021 | 7 | 260 | 647 | $124,530 | $46,223 |
| 2020 | 8 | 308 | 667 | $131,058 | $42,258 |
All Medicare Procedures & Services
27 procedure records from CMS Medicare Utilization — Page 1 of 2
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 19 | 65 | $23,920 | $6,314 | 26.4% |
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 20 | 73 | $14,089 | $4,240 | 30.1% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 23 | 39 | $6,591 | $1,603 | 24.3% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 18 | 29 | $7,163 | $1,473 | 20.6% |
| 99223 | Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | Facility | 2023 | 11 | 11 | $4,664 | $1,190 | 25.5% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2022 | 28 | 98 | $31,262 | $9,839 | 31.5% |
| 99232 | Follow-up hospital inpatient care per day, typically 25 minutes | Facility | 2022 | 30 | 167 | $27,990 | $8,761 | 31.3% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 39 | 71 | $15,657 | $4,084 | 26.1% |
| 99223 | Initial hospital inpatient care per day, typically 70 minutes | Facility | 2022 | 18 | 18 | $8,291 | $2,560 | 30.9% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 27 | 52 | $7,556 | $2,332 | 30.9% |
| 99238 | Hospital discharge day management, 30 minutes or less | Facility | 2022 | 20 | 20 | $3,450 | $1,056 | 30.6% |
| 99203 | New patient office or other outpatient visit, 30-44 minutes | Office | 2022 | 13 | 13 | $2,666 | $694.39 | 26.0% |
| 99215 | Established patient outpatient visit, total time 40-54 minutes | Office | 2021 | 37 | 150 | $40,500 | $15,895 | 39.2% |
| 99232 | Subsequent hospital inpatient care, typically 25 minutes per day | Facility | 2021 | 60 | 251 | $37,650 | $13,530 | 35.9% |
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Office | 2021 | 55 | 99 | $12,375 | $4,917 | 39.7% |
| 99223 | Initial hospital inpatient care, typically 70 minutes per day | Facility | 2021 | 27 | 31 | $12,555 | $4,713 | 37.5% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 34 | 67 | $13,400 | $4,447 | 33.2% |
| 99238 | Hospital discharge day management, 30 minutes or less | Facility | 2021 | 33 | 35 | $5,250 | $1,903 | 36.3% |
| 99203 | New patient outpatient visit, total time 30-44 minutes | Office | 2021 | 14 | 14 | $2,800 | $816.32 | 29.2% |
| 99215 | Established patient office or other outpatient, visit typically 40 minutes | Office | 2020 | 33 | 142 | $38,340 | $11,540 | 30.1% |
| 99232 | Subsequent hospital inpatient care, typically 25 minutes per day | Facility | 2020 | 65 | 207 | $31,050 | $11,442 | 36.8% |
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Office | 2020 | 55 | 104 | $20,800 | $5,736 | 27.6% |
| 99223 | Initial hospital inpatient care, typically 70 minutes per day | Facility | 2020 | 32 | 34 | $13,770 | $5,193 | 37.7% |
| 99213 | Established patient office or other outpatient visit, typically 15 minutes | Office | 2020 | 47 | 95 | $11,875 | $3,218 | 27.1% |
| 99238 | Hospital discharge day management, 30 minutes or less | Facility | 2020 | 47 | 56 | $8,400 | $3,060 | 36.4% |
About Dr. Robert Hamilton, MD
Dr. Robert Hamilton, MD is a Medical Oncology healthcare provider based in Jackson, Mississippi. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 06/21/2006. The National Provider Identifier (NPI) number assigned to this provider is 1154367837.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Robert Hamilton, MD has received a total of $13,131 in payments from pharmaceutical and medical device companies, with $57.33 received in 2024. These payments were reported across 870 transactions from 77 companies. The most common payment nature is "Food and Beverage" ($13,131).
As a Medicare-enrolled provider, Hamilton has provided services to 834 Medicare beneficiaries, totaling 1,970 services with total Medicare billing of $132,627. Data is available for 4 years (2020–2023), covering 27 distinct procedure/service records.
Practice Information
- Specialty Medical Oncology
- Location Jackson, MS
- Active Since 06/21/2006
- Last Updated 04/09/2014
- Taxonomy Code 207RX0202X
- Entity Type Individual
- NPI Number 1154367837
Products in Payments
- OPDIVO (Biological) $1,178
- KEYTRUDA (Biological) $958.20
- TECENTRIQ (Biological) $711.27
- Revlimid (Drug) $520.15
- IMBRUVICA (Drug) $373.58
- GILOTRIF (Drug) $334.21
- JAKAFI (Drug) $301.55
- DARZALEX (Biological) $287.09
- XTANDI (Drug) $282.60
- Nplate (Biological) $270.83
- Avastin (Biological) $231.55
- IBRANCE (Drug) $216.59
- CFN PleurX (Device) $209.77
- AFINITOR (Drug) $193.32
- Cabometyx (Drug) $179.64
- KISQALI (Drug) $174.04
- ELITEK (Drug) $170.28
- Neulasta (Biological) $160.95
- Pomalyst (Drug) $149.63
- Xtandi (Drug) $134.80
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Medical Oncology Doctors in Jackson
Dr. James Thigpen, Md, MD
Medical Oncology — Payments: $409,978
Dr. Natale Sheehan, Md, MD
Medical Oncology — Payments: $31,492
Tammy Young, M.d, M.D
Medical Oncology — Payments: $10,862
Dr. Louis Puneky, Md, MD
Medical Oncology — Payments: $9,764
Dr. Elizabeth Herrington, D.o, D.O
Medical Oncology — Payments: $8,764
Nicole Cleveland, Md, MD
Medical Oncology — Payments: $7,631